Presentation is loading. Please wait.

Presentation is loading. Please wait.

Depleting NQO1 expression levels inhibits growth of NSCLC cells in soft agar. Depleting NQO1 expression levels inhibits growth of NSCLC cells in soft agar.

Published byDebra Rich Modified over 5 years ago

Similar presentations

Presentation on theme: "Depleting NQO1 expression levels inhibits growth of NSCLC cells in soft agar. Depleting NQO1 expression levels inhibits growth of NSCLC cells in soft agar."— Presentation transcript:

1 Depleting NQO1 expression levels inhibits growth of NSCLC cells in soft agar.
Depleting NQO1 expression levels inhibits growth of NSCLC cells in soft agar. A, A549 shCtr-R and A549 shNQO1 cells were analyzed for their ability to form colonies and grow in soft agar. Photomicrographs shown are representative of experiments performed in sextuplet. B–D, graphical representation of enumerated colonies for A549 shNQO1, A549 shNQO1-B, and H292 shNQO1-B cells versus A549 shCtr-R, A549 shCtr-L, and H292 shCtr-L cells. B, P values for A549 shNQO1 versus A549 shCtr-R (P < ). C, P values for A549 shNQO1-B versus A549 shCtr-L (P = ). D, P values for H292 shNQO1-B versus H292 shCtr-L (P = ). Brian Madajewski et al. Mol Cancer Res 2016;14:14-25 ©2016 by American Association for Cancer Research

Download ppt "Depleting NQO1 expression levels inhibits growth of NSCLC cells in soft agar. Depleting NQO1 expression levels inhibits growth of NSCLC cells in soft agar."

Similar presentations

Pirh2 promotes p73 ubiquitination in vivo.

Pirh2 promotes p73 ubiquitination in vivo.
Interfering with HMGA2 expression blocks transformation in metastatic lung cancer cells. Interfering with HMGA2 expression blocks transformation in metastatic.

Interfering with HMGA2 expression blocks transformation in metastatic lung cancer cells. Interfering with HMGA2 expression blocks transformation in metastatic.
Knocking down Wnt3 increases the cells' response to trastuzumab and reduces cells' invasiveness. Knocking down Wnt3 increases the cells' response to trastuzumab.

Knocking down Wnt3 increases the cells' response to trastuzumab and reduces cells' invasiveness. Knocking down Wnt3 increases the cells' response to trastuzumab.
SIRT1 is downregulated in human gastric cancer (GC).

SIRT1 is downregulated in human gastric cancer (GC).
A, B, apoptosis analysis using Annexin V-FITC/PI was done on 5th, 7th, and 9th day after transfection either with si control or si AEBP1in U87MG and U138MG.

A, B, apoptosis analysis using Annexin V-FITC/PI was done on 5th, 7th, and 9th day after transfection either with si control or si AEBP1in U87MG and U138MG.
Effect of sustained suppression of HDAC2 in MKN-1 cells on in vitro tumorigenicity. Effect of sustained suppression of HDAC2 in MKN-1 cells on in vitro.

Effect of sustained suppression of HDAC2 in MKN-1 cells on in vitro tumorigenicity. Effect of sustained suppression of HDAC2 in MKN-1 cells on in vitro.
A, rate of proliferation of PC3 prostate cancer cells is greatly reduced by treatment with oligomers containing CpG motifs, as assessed by (a) soft agar.

A, rate of proliferation of PC3 prostate cancer cells is greatly reduced by treatment with oligomers containing CpG motifs, as assessed by (a) soft agar.
Activating mutation of Ras is associated with CDCP1 expression in NSCLC. A, NSCLC cell lines with Ras + B-Raf mutations and wild-type Ras were examined.

Activating mutation of Ras is associated with CDCP1 expression in NSCLC. A, NSCLC cell lines with Ras + B-Raf mutations and wild-type Ras were examined.
The expression of SPINDLIN1 in cancer tissues.

The expression of SPINDLIN1 in cancer tissues.
Induction of CDKN1A (□), MDM2 (◊), and GADD45A (○) in ML-1 cells by 50 cGy X-rays delivered at 0.28 cGy/min. Induction of CDKN1A (□), MDM2 (◊), and GADD45A.

Induction of CDKN1A (□), MDM2 (◊), and GADD45A (○) in ML-1 cells by 50 cGy X-rays delivered at 0.28 cGy/min. Induction of CDKN1A (□), MDM2 (◊), and GADD45A.
Effect of HA on hematopoietic recovery in tumor-bearing mice.

Effect of HA on hematopoietic recovery in tumor-bearing mice.
Induction of CDCP1 is regulated by Ras in NSCLC cells.

Induction of CDCP1 is regulated by Ras in NSCLC cells.
In the signal transduction pathway finder array, fold expression differences were analyzed through the SA Biosciences Web page, transferred into MATLAB,

In the signal transduction pathway finder array, fold expression differences were analyzed through the SA Biosciences Web page, transferred into MATLAB,
A. A. XPCKD and KIN17KD HeLa cells grow poorly 2 weeks after transfection. Forty-eight hours after transfection, cells were plated at the same density.

A. A. XPCKD and KIN17KD HeLa cells grow poorly 2 weeks after transfection. Forty-eight hours after transfection, cells were plated at the same density.
coTCRcys-transduced T cells control tumor growth in vivo.

coTCRcys-transduced T cells control tumor growth in vivo.
In vitro invasion assays were done in the Chemicon invasion chamber containing extracellular matrix. In vitro invasion assays were done in the Chemicon.

In vitro invasion assays were done in the Chemicon invasion chamber containing extracellular matrix. In vitro invasion assays were done in the Chemicon.
Expression of versican G3 domain enhanced breast cancer cell mammosphere formation. Expression of versican G3 domain enhanced breast cancer cell mammosphere.

Expression of versican G3 domain enhanced breast cancer cell mammosphere formation. Expression of versican G3 domain enhanced breast cancer cell mammosphere.
Protein expression profile in a dasatinib-resistant cell line.

Protein expression profile in a dasatinib-resistant cell line.
Colony-forming capacity of CD34+ cells with and without CLL-1 expression. Colony-forming capacity of CD34+ cells with and without CLL-1 expression. CD34+

Colony-forming capacity of CD34+ cells with and without CLL-1 expression. Colony-forming capacity of CD34+ cells with and without CLL-1 expression. CD34+
Imatinib mesylate inhibits PDGF-mediated ERK and Akt activation.

Imatinib mesylate inhibits PDGF-mediated ERK and Akt activation.

Similar presentations

Ads by Google